(Q36618400)

15 August 2017

1 reference

title

Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine (English)

1 reference

15 August 2017

author name string

Emilio Fernández-Varón

series ordinal

1

1 reference

15 August 2017

Lucía Villamayor

series ordinal

2

1 reference

15 August 2017

publication date

9 October 2006

1 reference

15 August 2017

published in

The Veterinary Journal

1 reference

15 August 2017

volume

174

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

33-41

1 reference

Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Endogenous haemopoietic growth factors in neutropenia and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Cytokines and anti-cytokine therapy: clinical potential for treatment of feline disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Colony-stimulating factors in the management of neutropenia and its complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Hematopoietic growth factors for the treatment of aplastic anemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Granulocyte colony-stimulating factor deficiency in a rottweiler with chronic idiopathic neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

The colony stimulating factors. Discovery, development, and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Pharmacology of the colony-stimulating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Effect of Recombinant Canine Granulocyte Colony‐stimulating Factor on Peripheral Blood Neutrophil Counts in Normal Cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Guidelines on the use of colony-stimulating factors in haematological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

G-CSF: a key regulator of neutrophil production, but that's not all!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

An adult dog with cyclic neutropenia treated by lentivirus- mediated delivery of granulocyte colony-stimulating factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

Haematological, bone marrow and clinical chemical changes in neonatal foals given canine recombinant granulocyte-colony stimulating factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2006.08.001

10.1016/J.TVJL.2006.08.001

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference